UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies

British journal of cancer, 2014-12, Vol.111 (12), p.2328-2341

2014

Volltextzugriff (PDF)

An open-label phase II study to evaluate PT2977 for the treatment of von hippel-lindau disease associated renal cell carcinoma

Annals of oncology, 2018-10, Vol.29, p.viii328-viii328

2018

Volltextzugriff (PDF)

Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy

Nanotechnology, 2011-01, Vol.22 (3), p.035101-035101

2011

Volltextzugriff (PDF)

921TiPAn open-label phase II study to evaluate PT2977 for the treatment of von hippel-lindau disease associated renal cell carcinoma

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

PCR181 Health-Related Quality-of-Life of Patients Treated with Repotrectinib for Neurotrophic Tyrosine Receptor Kinase (NTRK)-Positive Advanced Solid Tumors: Results from TRIDENT-1

Value in health, 2023-12, Vol.26 (12), p.S484

2023

Volltextzugriff (PDF)

1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial

Annals of oncology, 2023-10, Vol.34, p.S787-S788

2023

Volltextzugriff (PDF)

Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)

European journal of cancer (1990), 2022-10, Vol.174, p.S75-S76

2022

Volltextzugriff (PDF)

A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC

Annals of oncology, 2019-10, Vol.30, p.v361-v362

2019

Volltextzugriff (PDF)

911PD - A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC

Annals of oncology, 2019-10, Vol.30, p.v361-v362

2019

Volltextzugriff (PDF)

LBA26 Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease

Annals of oncology, 2020-09, Vol.31, p.S1158-S1158

2020

Volltextzugriff (PDF)

911PDA first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Effect of potassium and zinc application on macro nutrient uptake of red gram under Vertisols

International Journal of Chemical Research and Development, 2019-07, Vol.1 (2), p.8-10

2019

Volltextzugriff (PDF)

Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer

Biomaterials, 2012-10, Vol.33 (29), p.7164-7173

2012

Volltextzugriff (PDF)

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Nature medicine, 2021-05, Vol.27 (5), p.802-805

2021

Volltextzugriff (PDF)

Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer

PloS one, 2012-09, Vol.7 (9), p.e44299-e44299

2012

Volltextzugriff (PDF)

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

The New England journal of medicine, 2021-11, Vol.385 (22), p.2036-2046

2021

Volltextzugriff (PDF)

A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events

Journal of cell science, 2011-05, Vol.124 (Pt 9), p.1453-1464

2011

Volltextzugriff (PDF)

Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Nature medicine, 2021-10, Vol.27 (10), p.1849-1849

2021

Volltextzugriff (PDF)

Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy

Nanomedicine (London, England), 2016-03, Vol.11 (5), p.479-494

2016

Volltextzugriff (PDF)

sup 64^Cu-labeled dimeric glucosamine conjugates and their evaluation in metastatic melanoma cancer cells

The Journal of nuclear medicine (1978), 2017-05, Vol.58, p.676

2017

Volltextzugriff (PDF)

An open-label phase II study to evaluate PT2977 for the treatment of von Hippel-Lindau disease-associated renal cell carcinoma

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.TPS680-TPS680

2019

Volltextzugriff (PDF)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer

PloS one, 2012-09, Vol.7 (9)

2012

Volltextzugriff (PDF)

To assess the importance of Nidana Parivarjan in the treatment of Urdhvag Amlapitta with Guduchi Satva

Journal of Ayurveda and Integrated Medical Sciences (JAIMS), 2020-08, Vol.5 (4), p.16-20

2020

Volltextzugriff (PDF)

Inhibition of hypoxia-inducible factor-2[alpha] in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Nature medicine, 2021-05, Vol.27 (5), p.802

2021

Volltextzugriff (PDF)

Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.333-333

2021

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(46)
Dissertationen
(2)

Sprache

Englisch
(48)

Erscheinungsjahr

n.n

Thema

Science & Technology
(13)
Humans
(10)
Life Sciences & Biomedicine
(8)
Female
(7)
Breast Cancer
(6)
Nanoparticles - Chemistry
(6)
Science & Technology - Other Topics
(6)
Animals
(5)
Cell Line, Tumor
(5)
Nanoparticles
(5)
Nanoscience & Nanotechnology
(5)
Cancer
(4)
Lactic Acid - Chemistry
(4)
Materials Science
(4)
Mice
(4)
Particle Size
(4)
Physical Sciences
(4)
Polyglycolic Acid - Chemistry
(4)
Technology
(4)
Antineoplastic Agents - Therapeutic Use
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies

An open-label phase II study to evaluate PT2977 for the treatment of von hippel-lindau disease associated renal cell carcinoma

Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy

921TiPAn open-label phase II study to evaluate PT2977 for the treatment of von hippel-lindau disease associated renal cell carcinoma

PCR181 Health-Related Quality-of-Life of Patients Treated with Repotrectinib for Neurotrophic Tyrosine Receptor Kinase (NTRK)-Positive Advanced Solid Tumors: Results from TRIDENT-1

1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial

Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)

A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC

911PD - A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC

LBA26 Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease

911PDA first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC

Effect of potassium and zinc application on macro nutrient uptake of red gram under Vertisols

Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events

Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy

sup 64^Cu-labeled dimeric glucosamine conjugates and their evaluation in metastatic melanoma cancer cells

An open-label phase II study to evaluate PT2977 for the treatment of von Hippel-Lindau disease-associated renal cell carcinoma

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer

To assess the importance of Nidana Parivarjan in the treatment of Urdhvag Amlapitta with Guduchi Satva

Inhibition of hypoxia-inducible factor-2[alpha] in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC)

Suchergebnisse filtern